Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.53 |
| ▸ | GPR183 | P32249 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2372318 | 0.90 | GPR119 (0.48) | GPR119GPR183KCNH2HRH3 | |
| SCHEMBL2371581 | 0.90 | GPR119 (0.48) | GPR119GPR183KCNH2HRH3 | |
| SCHEMBL3315647 | 0.89 | GPR119 (0.45) | GPR119GPR183KCNH2HDAC4 | |
| SCHEMBL2399158 | 0.89 | GPR119 (0.49) | GPR119GPR183KCNH2HDAC4 | |
| SCHEMBL2371717 | 0.87 | GPR119 (0.51) | GPR119GPR183KCNH2HRH3HDAC4 | |
| SCHEMBL2372433 | 0.87 | GPR119 (0.51) | GPR119GPR183KCNH2HRH3HDAC4 | |
| SCHEMBL2372004 | 0.87 | GPR119 (0.51) | GPR119GPR183KCNH2HRH3HDAC4 | |
| SCHEMBL2244527 | 0.87 | GPR119 (0.47) | GPR119GPR183KCNH2 | |
| SCHEMBL2566410 | 0.87 | GPR119 (0.58) | GPR119GPR183KCNH2HRH2HRH1 | |
| SCHEMBL2404798 | 0.86 | GPR119 (0.47) | GPR119GPR183KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109703-A1 | Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-02 | — | — | US | claimed |
| EP-2547339-A1 | COMBINATION OF A GPR119 AGONIST AND THE DPP-IV INHIBITOR LINAGLIPTIN FOR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Boehringer Ingelheim International GmbH (DE) | 2013-01-23 | — | — | EP | claimed |
| WO-2011113947-A1 | COMBINATION OF A GPR119 AGONIST AND THE DPP-IV INHIBITOR LINAGLIPTIN FOR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-22 | — | — | WO | claimed |
| US-20100022591-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-28 | — | — | US | claimed |
| US-20130109703-A1 | Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-02 | — | — | US | disclosed |
| EP-2547339-A1 | COMBINATION OF A GPR119 AGONIST AND THE DPP-IV INHIBITOR LINAGLIPTIN FOR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Boehringer Ingelheim International GmbH (DE) | 2013-01-23 | — | — | EP | disclosed |
| EP-2114931-B1 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2011-11-02 | — | — | EP | disclosed |
| EP-2383270-A1 | Piperidine GPCR agonists | Prosidion Limited (GB) | 2011-11-02 | — | — | EP | disclosed |
| WO-2011113947-A1 | COMBINATION OF A GPR119 AGONIST AND THE DPP-IV INHIBITOR LINAGLIPTIN FOR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-22 | — | — | WO | disclosed |
| US-20100022591-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| US-20100022591-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| US-20100022591-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| WO-2008081205-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022591-A1 | PIPERIDINE GPCR AGONISTS | GPR119, GPR27, GLP1R | GPR119 1/4885GPR183 45/4885KCNH2 1128/4885 |
| US-20130109703-A1 | Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions | GPR119, DPP4, GLP1R | GPR119 1/4885GPR183 62/4885KCNH2 3673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.